Creating the future of medical technology in South Africa

South Africa's healthcare system faces a paradox that costs billions annually: the nation imports cutting-edge medical technology while functional equipment decays unused in public hospital wards. This contradiction exposes a systemic failure in how African healthcare adopts, maintains, and innovates around critical medical infrastructure—a gap that extends far beyond procurement mismanagement into questions of local innovation capacity, skills development, and economic sovereignty.

## Why does South Africa import medical technology instead of building it locally?

The answer lies in a combination of historical dependency, skill gaps, and perceived risk aversion. South Africa's medical technology sector remains underdeveloped relative to its manufacturing and engineering capabilities. While the country boasts world-class universities and a growing biotech ecosystem, the pipeline from research to commercialised, hospital-ready medical devices remains fragmented. Multinational suppliers dominate procurement channels, offering established products with regulatory certifications that risk-averse hospital administrators prefer over unproven local alternatives—even when those alternatives could be cheaper and more maintainable.

Between 2018 and 2023, South Africa's healthcare sector imported an estimated R45–50 billion (USD 2.4–2.7 billion) in medical equipment annually, according to trade data analysis. Yet audits consistently reveal that 20–30% of acquired equipment sits non-functional due to inadequate maintenance protocols, spare parts shortages, and insufficient technical training. The economic loss is staggering: broken dialysis machines, non-operational imaging equipment, and defunct monitoring systems directly translate to delayed diagnoses, preventable deaths, and wasted taxpayer investment.

## What would breaking this import-dependency cycle require?

Three interconnected interventions are essential. First, government and private healthcare institutions must create preferential procurement frameworks that incentivise local medical device manufacturing—not through protectionism, but through performance-based contracts that reward reliability, cost-effectiveness, and local job creation. Second, universities and the Department of Science and Innovation must fund translational research pipelines that move laboratory innovations into production-ready devices within 3–5 years, bridging the notorious "valley of death" between invention and commercialisation. Third, healthcare workers—from biomedical engineers to ward nurses—require systematic upskilling in equipment maintenance and troubleshooting, transforming broken devices from liabilities into assets.

The opportunity is substantial. South Africa's engineering and manufacturing sectors possess the technical depth to produce diagnostic devices, prosthetics, surgical instruments, and monitoring equipment that meet international standards while serving African markets with pricing and after-sales support tailored to local realities. Companies like Mechatronics Industries and emerging startups in the medtech space have already demonstrated proof-of-concept, yet expansion remains constrained by capital access and procurement barriers.

## How does this affect South African investors?

The convergence of healthcare need, technological capability, and underinvestment creates a rare market opening. Venture capital and development finance targeting local medical device manufacturers can achieve both social impact and 25–35% internal rates of return within seven years, particularly in higher-volume segments like diagnostic equipment and patient monitoring systems. Additionally, businesses that solve the maintenance-and-training problem—through service contracts, spare parts networks, and technician certification programs—address an immediate market need currently unmet.

The healthcare sector's dependency on imports is not inevitable; it reflects choices about investment, risk, and institutional capacity. Breaking the cycle requires deliberate policy alignment, capital mobilisation, and belief that South African innovation can serve African healthcare—generating returns while reclaiming billions currently exported as fees to foreign suppliers.